A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492 BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.21492 Open DOISearch in Google Scholar

2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–44. doi: 10.1200/JCO.2005.04.4859 GovindanR PageN MorgenszternD ReadW TierneyR VlahiotisA Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 2006 24 4539 44 10.1200/JCO.2005.04.4859 Open DOISearch in Google Scholar

3. Dómine M, Moran T, Isla D, Martí JL, Sullivan I, Provencio M, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol 2020; 22: 245–55. doi: 10.1007/s12094-020-02295-w DómineM MoranT IslaD MartíJL SullivanI ProvencioM SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) Clin Transl Oncol 2020 22 245 55 10.1007/s12094-020-02295-w Open DOISearch in Google Scholar

4. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 2004; 30: 359–68. doi: 10.1016/j.ctrv.2003.12.006 SekineI YamamotoN KunitohH OheY TamuraT KodamaT SaijoN Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials Cancer Treat Rev 2004 30 359 68 10.1016/j.ctrv.2003.12.006 Open DOISearch in Google Scholar

5. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res 2002; 93: 15–23. doi: 10.1111/j.1349-7006.2002.tb01195.x MoritaT A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world Jpn J Cancer Res 2002 93 15 23 10.1111/j.1349-7006.2002.tb01195.x Open DOISearch in Google Scholar

6. Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in elderly patients. Cancer 2010; 116: 1192–200. doi: 10.1002/cncr.24833 PallisAG ShepherdFA LacombeD GridelliC Treatment of small-cell lung cancer in elderly patients Cancer 2010 116 1192 200 10.1002/cncr.24833 Open DOISearch in Google Scholar

7. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines^®). Small cell lung cancer. [internet]. 2023. [cited 2023 Oct 9]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462 National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines^®) Small cell lung cancer. [internet] 2023 [cited 2023 Oct 9]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462 Search in Google Scholar

8. Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 839–53. doi: 10.1016/j.annonc.2021.03.207 DingemansAC FrühM ArdizzoniA BesseB Faivre-FinnC HendriksLE Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2021 32 839 53 10.1016/j.annonc.2021.03.207 Open DOISearch in Google Scholar

9. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998; 28: 463–73. doi: 10.1093/jjco/28.8.463 SekineI FukudaH KunitohH SaijoN Cancer chemotherapy in the elderly Jpn J Clin Oncol 1998 28 463 73 10.1093/jjco/28.8.463 Open DOISearch in Google Scholar

10. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626–31. doi: 10.1200/JCO.2004.02.175 TalaricoL ChenG PazdurR Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration J Clin Oncol 2004 22 4626 31 10.1200/JCO.2004.02.175 Open DOISearch in Google Scholar

11. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20: 3054–60. doi: 10.1200/JCO.2002.12.071 TakadaM FukuokaM KawaharaM SugiuraT YokoyamaA YokotaS Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J Clin Oncol 2002 20 3054 60 10.1200/JCO.2002.12.071 Open DOISearch in Google Scholar

12. Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, et al. Similar outcome of elderly patients in intergroup trial 0096. Cancer 2000; 89: 1953–60. doi: 10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.3.CO;2-Y YuenAR ZouG TurrisiAT SauseW KomakiR WagnerH Similar outcome of elderly patients in intergroup trial 0096 Cancer 2000 89 1953 60 10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.3.CO;2-Y Open DOISearch in Google Scholar

13. Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005; 103: 2349–54. doi: 10.1002/cncr.21034 SchildSE StellaPJ BrooksBJ MandrekarS BonnerJA McGinnisWL Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly Cancer 2005 103 2349 54 10.1002/cncr.21034 Open DOISearch in Google Scholar

14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706–14. doi: 10.1097/JTO.0b013e31812f3c1a GoldstrawP CrowleyJ ChanskyK GirouxDJ GroomePA Rami-PortaR The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2007 2 706 14 10.1097/JTO.0b013e31812f3c1a Open DOISearch in Google Scholar

15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026 EisenhauerEA TherasseP BogaertsJ SchwartzLH SargentD FordR New response evaluation criteria in solid tumours: revised RECIST guideline. (version 1.1) Eur J Cancer 2009 45 228 47 10.1016/j.ejca.2008.10.026 Open DOISearch in Google Scholar

16. Gridelli C, Casaluce F, Sgambato A, Monaco F, Guida C. Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question. Transl Lung Cancer Res 2016; 5: 150–4. doi: 10.21037/tlcr.2016.03.03 GridelliC CasaluceF SgambatoA MonacoF GuidaC Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question Transl Lung Cancer Res 2016 5 150 4 10.21037/tlcr.2016.03.03 Open DOISearch in Google Scholar

17. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 1998; 82: 836–41. doi: 10.1002/(sici)1097-0142(19980301)82:5<836::aid-cncr6>3.0.co;2-h JeremicB ShibamotoY AcimovicL MilisavljevicS Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study Cancer 1998 82 836 41 10.1002/(sici)1097-0142(19980301)82:5<836::aid-cncr6>3.0.co;2-h Open DOISearch in Google Scholar

18. Shimizu T, Sekine I, Sumi M, Ito Y, Yamada K, Nokihara H, et al. Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older. Jpn J Clin Oncol 2007; 37: 181–5. doi: 10.1093/jjco/hym005 ShimizuT SekineI SumiM ItoY YamadaK NokiharaH Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older Jpn J Clin Oncol 2007 37 181 5 10.1093/jjco/hym005 Open DOISearch in Google Scholar

19. Okamoto K, Okamoto I, Takezawa K, Tachibana I, Fukuoka M, Nishimura Y, et al. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. Jpn J Clin Oncol 2010; 40: 54–9. doi: 10.1093/jjco/hyp137 OkamotoK OkamotoI TakezawaK TachibanaI FukuokaM NishimuraY Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients Jpn J Clin Oncol 2010 40 54 9 10.1093/jjco/hyp137 Open DOISearch in Google Scholar

20. Shukuya T, Takahashi T, Harada H, Ono A, Akamatsu H, Taira T, et al. Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older. Jpn J Clin Oncol 2013; 43: 176–83. doi: 10.1093/jjco/hys197 ShukuyaT TakahashiT HaradaH OnoA AkamatsuH TairaT Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older Jpn J Clin Oncol 2013 43 176 83 10.1093/jjco/hys197 Open DOISearch in Google Scholar

21. Okamoto K, Okamoto I, Takeda M, Kobayashi S, Takeda K, Nakamatsu K, et al. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer. Jpn J Clin Oncol 2014; 44: 743–8. doi: 10.1093/jjco/hyu071 OkamotoK OkamotoI TakedaM KobayashiS TakedaK NakamatsuK A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer Jpn J Clin Oncol 2014 44 743 8 10.1093/jjco/hyu071 Open DOISearch in Google Scholar

22. Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, et al. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol 2015; 33: 4240–6. doi: 10.1200/JCO.2015.62.4270 CorsoCD RutterCE ParkHS Lester-CollNH KimAW WilsonLD Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer J Clin Oncol 2015 33 4240 6 10.1200/JCO.2015.62.4270 Open DOISearch in Google Scholar

23. Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, et al. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemother Pharmacol 2016; 78: 769–74. doi: 10.1007/s00280-016-3135-2 KuboT FujiwaraK HottaK OkadaT KuyamaS HaritaS A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102 Cancer Chemother Pharmacol 2016 78 769 74 10.1007/s00280-016-3135-2 Open DOISearch in Google Scholar

24. Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, et al. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer 2017; 17: 377. doi: 10.1186/s12885-017-3353-y MisumiY OkamotoH SasakiJ MasudaN IshiiM ShimokawaT Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604 BMC Cancer 2017 17 377 10.1186/s12885-017-3353-y Open DOISearch in Google Scholar

25. Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, et al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer 2019; 125: 382–90. doi: 10.1002/cncr.31813 StinchcombeTE FanW SchildSE VokesEE BogartJ LeQT A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients Cancer 2019 125 382 90 10.1002/cncr.31813 Open DOISearch in Google Scholar

26. Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, et al. Compliance and outcome of elderly patients treated in the concurrent Once-Daily versus Twice-Daily radiotherapy (CONVERT) trial. J Thorac Oncol 2019; 14: 63–71. doi: 10.1016/j.jtho.2018.09.027 ChristodoulouM BlackhallF MistryH LeylekA KnegjensJ RemouchampsV Compliance and outcome of elderly patients treated in the concurrent Once-Daily versus Twice-Daily radiotherapy (CONVERT) trial J Thorac Oncol 2019 14 63 71 10.1016/j.jtho.2018.09.027 Open DOISearch in Google Scholar

27. Killingberg KT, Grønberg BH, Slaaen M, Kirkevold Ø, Halvorsen TO. Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited-stage SCLC. J Thorac Oncol 2023; 18: 803–12. doi: 10.1016/j.jtho.2023.01.012 KillingbergKT GrønbergBH SlaaenM KirkevoldØ HalvorsenTO Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited-stage SCLC J Thorac Oncol 2023 18 803 12 10.1016/j.jtho.2023.01.012 Open DOISearch in Google Scholar

28. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33: 3199–212. doi:10.1200/JCO.2015.62.3488 SmithTJ BohlkeK LymanGH CarsonKR CrawfordJ CrossSJ Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 2015 33 3199 212 10.1200/JCO.2015.62.3488 Open DOISearch in Google Scholar

29. Crawford J, Caserta C, Roila F, Group EGW. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010; 21(Suppl 5): v248–51. doi: 10.1093/annonc/mdq195 CrawfordJ CasertaC RoilaF GroupEGW Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications Ann Oncol 2010 21 Suppl 5 v248 51 10.1093/annonc/mdq195 Open DOISearch in Google Scholar

30. Fujiwara T, Kenmotsu H, Naito T, Kawamura T, Mamesaya N, Kotake M, et al. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. Cancer Chemother Pharmacol 2017; 79: 1229–37. doi: 10.1007/s00280-017-3324-7 FujiwaraT KenmotsuH NaitoT KawamuraT MamesayaN KotakeM The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum Cancer Chemother Pharmacol 2017 79 1229 37 10.1007/s00280-017-3324-7 Open DOISearch in Google Scholar

31. Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 1987; 5: 592–600. doi: 10.1200/JCO.1987.5.4.592 KiesMS MiraJG CrowleyJJ ChenTT PazdurR GrozeaPN Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study J Clin Oncol 1987 5 592 600 10.1200/JCO.1987.5.4.592 Open DOISearch in Google Scholar

32. Oshita F, Kurata T, Kasai T, Fakuda M, Yamamoto N, Ohe Y, et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 1995; 86: 1198–202. doi: 10.1111/j.1349-7006.1995.tb03315.x OshitaF KurataT KasaiT FakudaM YamamotoN OheY Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions Jpn J Cancer Res 1995 86 1198 202 10.1111/j.1349-7006.1995.tb03315.x Open DOISearch in Google Scholar

33. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30: 1692–8. doi: 10.1200/JCO.2011.40.4905 RossiA Di MaioM ChiodiniP RuddRM OkamotoH SkarlosDV Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data J Clin Oncol 2012 30 1692 8 10.1200/JCO.2011.40.4905 Open DOISearch in Google Scholar

34. Jara C, Gómez-Aldaraví JL, Tirado R, Meseguer VA, Alonso C, Fernández A. Small-cell lung cancer in the elderly--is age of patient a relevant factor? Acta Oncol 1999; 38: 781–6. doi: 10.1080/028418699432941 JaraC Gómez-AldaravíJL TiradoR MeseguerVA AlonsoC FernándezA Small-cell lung cancer in the elderly--is age of patient a relevant factor? Acta Oncol 1999 38 781 6 10.1080/028418699432941 Open DOISearch in Google Scholar

35. Kasahara N, Imai H, Kaira K, Mori K, Wakuda K, Ono A, et al. Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. Radiol Oncol 2015; 49: 409–15. doi: 10.1515/raon-2015-0037 KasaharaN ImaiH KairaK MoriK WakudaK OnoA Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy Radiol Oncol 2015 49 409 15 10.1515/raon-2015-0037 Open DOISearch in Google Scholar